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Multi-Organ Transplant Program, Dalhousie University, Halifax, Nova Scotia, CanadaWarm ischemia time is a potentially modiﬁable insult to
transplanted kidneys, but little is known about its effect on
long-term outcomes. Here we conducted a study of United
States kidney transplant recipients (years 2000–2013) to
determine the association between warm ischemia time
(the time from organ removal from cold storage to
reperfusion with warm blood) and death/graft failure.
Times under 10 minutes were potentially attributed to
coding error. Therefore, the 10-to-under-20-minute interval
was chosen as the reference group. The primary outcome
was mortality and graft failure (return to chronic dialysis or
preemptive retransplantation) adjusted for recipient,
donor, immunologic, and surgical factors. The study
included 131,677 patients with 35,901 events. Relative to
the reference patients, times of 10 to under 20, 20 to under
30, 30 to under 40, 40 to under 50, 50 to under 60, and 60
and more minutes were associated with hazard ratios of
1.07 (95% conﬁdence interval, 0.99–1.15), 1.13 (1.06–1.22),
1.17 (1.09–1.26), 1.20 (1.12–1.30), and 1.23 (1.15–1.33) for
the composite event, respectively. Association between
prolonged warm ischemia time and death/graft failure
persisted after stratiﬁcation by donor type (living vs.
deceased donor) and delayed graft function status. Thus,
warm ischemia time is associated with adverse long-term
patient and graft survival after kidney transplantation.
Identifying strategies to reduce warm ischemia time is an
important consideration for future study.
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648T ransplantation has been an important contribution tomedicine and the care of patients with terminal organfailure. Given the relative scarcity of organs, strategies
to lengthen graft and patient survival are an important area of
research. One of the more intensely studied areas is the
ischemia–reperfusion injury that all solid organs develop after
implantation. Prior studies have shown that maladaptive
responses to ischemia impair organ recovery. Putative
molecular mechanisms include generation of reactive oxygen
species, induction of apoptosis, and stimulation of the innate
and adaptive immune system.1–3 These mechanisms may lead
to kidney transplants that do not function immediately after
surgery (delayed graft function), which in turn is associated
with poor long-term graft and patient survival.4,5
A great deal of research in kidney transplantation has
focused on developing better preservation solutions to
ameliorate damage and subsequent delayed graft function due
to prolonged cold storage time (cold ischemia). Despite
advances in this area, recent studies show that every addi-
tional hour of cold storage time increases the risk of graft
failure or death after transplantation.6 In contrast, only a few
studies have examined the effect of prolonged warm ischemia
times (removal from cold storage to reperfusion with warm
blood, including surgical anastomotic time) on outcomes.7–10
These studies ﬁnd that longer warm ischemia times are
associated with more delayed graft function, longer stays in
hospital, and worse graft and patient survival. While infor-
mative, studies thus far have been small single-center retro-
spective cohorts and may not be generalizable to other centers
with different practice patterns or surgical expertise.
Therefore, the objective of this study was to examine the
association of warm ischemia time with patient and graft
survival after kidney transplantation in a large cohort of US
kidney transplant recipients. We hypothesized that increases
in warm ischemia time would be associated with a higher risk
of mortality and graft failure.RESULTS
The eligible cohort consisted of 204,263 patients after exclu-
sions (Figure 1). Overall, 131,677 patients had a documented
warm ischemia time. The baseline characteristics of those with
and without documented warm ischemia times are noted inKidney International (2016) 89, 648–658
Figure 1 | Derivation of study cohort. SRTR, Scientiﬁc Registry of
Transplant Recipients.
KK Tennankore et al.: Warm time and transplant outcomes c l i n i ca l i nves t iga t ionTable 1. There were more deceased-donor versus living-donor
recipients in the groupwith reportedwarm ischemia times, and
notable differences in the type of induction therapy between the
2 groups. Characteristics of patients at each warm ischemia
time increment are noted in Table 2. In general, patients with
longer warm ischemia times were more likely to be deceased-
donor recipients and had a longer cold ischemia time and
higher body mass index and comorbidity burden compared to
those patients with shorter times. Of the 13,456 patients with
times of<10minutes, 4647 (35%) and 9099 (68%) had awarm
ischemia time of 0 minutes and #1 minute, respectively. The
proportion of missing warm ischemia times varied with year of
transplantation. Fifty percent of patients had missing times
from 2000 to 2004 compared with 29% from 2005 to 2013.
Center differences in reporting of warm ischemia time are
noted in Figure 2. Overall, 150 centers (responsible for 83,787
patients) had reporting rates of $75%. The distribution of
warm ischemia time is noted in Figure 3. Median warm
ischemia time was 35 minutes (Q1–Q3: 27–45), and 38,403
patients (29%) had a time of 30 to<40 minutes. Three percent
and 13% of patients had warm ischemia times of 10 to <20
minutes and $60 minutes, respectively.
Primary outcome (death and graft failure)
In the study cohort of patients with reported warm ischemia
time, there were 35,901 events (20,032 graft failures and 15,869
patients who died with graft function). Median follow-up was
3.98 years (interquartile range: 1.93–6.93, 606,057 patient-
years at risk). Compared with patients with warm ischemia
times of 10 to <20 minutes, increases in warm ischemia time
were associated with an increased risk of the composite
outcome (log rank P < 0.0001, Figure 4). Five- and 10-year
survival probabilities for each warm time increment are
noted in Table 3. Relative hazards and 95% conﬁdence in-
tervals for confounding variables are noted in Supplementary
Table S1 online.
Compared with patients with warm ischemia times of
10 to <20 minutes, times of $30 minutes were associatedKidney International (2016) 89, 648–658with a statistically higher adjusted relative hazard for the
composite event of death or graft failure (Table 4). The
highest category of warm ischemia time ($60 minutes) was
associated with a 23% increase in the adjusted relative hazard
for death or graft failure (hazard ratio 1.23, 95% conﬁdence
interval 1.15–1.33). The adjusted relative hazard was com-
parable for component outcomes of death with graft function,
or death-censored graft failure. The result of the analysis after
multiple imputation was similar to the complete case analysis.
Sensitivity analysis
Relative hazards before and after 1-year follow-up are noted
in Supplementary Table S2. The hazard ratio for the category
of $60 minutes was higher at 1 year compared to >1 year,
whereas point estimates for most other categories were
similar. Point estimates were similar among patients coming
from centers with $75% warm ischemia time reporting or
from a more contemporary era (2005–2013). Furthermore,
the association between prolonged warm ischemia time and
outcome persisted after restricting the cohort to ﬁrst kidney
transplants and after using broader warm ischemia time
categories (0 to <10, 10 to <30, 30 to <60, 60 to <90,
and $90 minutes, Table 5).
Subgroup analysis
Point estimates were similar among those with or without
delayed graft function (Supplementary Table S3). Point esti-
mates were higher for each warm time category (compared to
the reference group) in the separate analysis conducted among
deceased-donor recipients versus the analysis conducted
among living-donor recipients. Speciﬁcally, the adjusted
relative hazard for deceased-donor recipients with warm
ischemia times of $60 minutes versus 10 to 20 minutes was
1.32 (1.20–1.44) versus 1.14 (1.01–1.29) among living-donor
recipients (Supplementary Table S4). Finally, in the subgroup
of donation-after-circulatory-death recipients, there was a
higher adjusted relative hazard for the primary outcome, but
more uncertainty in the estimate (Supplementary Table S4).
DISCUSSION
In this study we identiﬁed that progressively longer warm
ischemia times were associated with an increased risk of death
or graft failure even after multivariable adjustment for donor
and recipient factors. The association between a prolonged
warm ischemia time and outcome persisted in subgroups of
living- and deceased-donor recipients, and was maintained in
sensitivity analyses using different cohort restrictions. Finally,
there was considerable variation in the reporting of warm
ischemia time by center.
To our knowledge, this is the ﬁrst study to quantify the
effect of prolonged warm ischemia time in a large, multi-
center, contemporary cohort, and it highlights a potentially
modiﬁable factor for long-term patient and graft survival.
Although warm ischemia is well known to cause acute kidney
injury after partial nephrectomy in non-transplant pa-
tients,11–13 there have been fewer clinical studies examining649
Table 1 | Baseline characteristics of eligible study cohort stratiﬁed by presence or absence of documented warm ischemia time
Variable
Proportion of patients
in ﬁnal study cohort
with missing data
Eligible study cohort
N [ 204,263
Final study cohort
(warm time present)
N [ 131,677
Warm time missing
N [ 72,586
Donor characteristics
Age (mean years  SD) <1a 39  16 39  16 39  16
Height (mean meters  SD) <1a 1.7  0.1 1.7  0.1 1.7  0.1
Weight (mean kg  SD) 0a 79  23 79  23 78  22
Male sex 0 106,200 (52) 68,828 (52) 37,372 (51)
Race <1
White 143,571 (70) 92,276 (70) 51,295 (71)
Black 26,406 (13) 17,318 (13) 9088 (13)
Hispanic 26,712 (13) 17,260 (13) 9452 (13)
Other 7572 (4) 4822 (4) 2750 (4)
Body mass index categories 2
<20 15,533 (8) 9998 (8) 5535 (8)
20–24.9 64,269 (33) 41,591 (32) 22,678 (33)
25–29.9 69,010 (35) 45,162 (35) 23,848 (35)
30–34.9 32,782 (17) 21,561 (17) 11,221 (16)
$35 16,125 (8) 10,606 (8) 5519 (8)
Donor type 0
Deceased 123,530 (60) 81,090 (62) 42,440 (58)
Standard criteria 102,825 (50) 67,988 (52) 34,837 (48)
Expanded criteria 20,705 (10) 13,102 (10) 7603 (10)
Living donor 80,733 (40) 50,587 (38) 30,146 (42)
Donor cause of death 0a
Anoxia 24,087 (20) 16,447 (20) 7640 (18)
Cerebrovascular accident 46,026 (37) 29,375 (36) 16,651 (39)
Head trauma 49,583 (40) 32,754 (40) 16,829 (40)
Other 3832 (3) 2514 (3) 1318 (3)
Donation after circulatory death <1a 12,952 (10) 9199 (11) 3753 (9)
Donor hepatitis C positive <1a 3231 (3) 1858 (2) 1373 (3)
History of diabetes mellitus 10 7888 (4) 5172 (4) 2716 (5)
Hypertension 1a 32,848 (27) 21,558 (27) 11,290 (27)
Donor serum creatinine >1.5 mg/dl <1a 18,904 (15) 12,405 (15) 6499 (15)
Pulsatile perfusion <1a 31,811 (26) 22,043 (27) 9799 (23)
Surgical characteristics
Cold ischemia time (hours) 8 12 (2–20) 12 (2–20) 13 (2–21)
Immunologic characteristics
HLA mismatches <1
0 21,003 (10) 13,162 (10) 7841 (11)
1 7549 (4) 4577 (3) 2972 (4)
2 19,260 (9) 12,101 (9) 7159 (10)
3 38,451 (19) 24,478 (19) 13,973 (19)
4 42,689 (21) 27,975 (21) 14,714 (20)
5 49,273 (24) 32,407 (25) 16,866 (23)
6 25,198 (12) 16,427 (13) 8771 (12)
Induction type 0
Interleukin-2 receptor antagonist 52,679 (26) 33,250 (25) 19,429 (27)
Anti-thymocyte globulin 81,720 (40) 56,666 (43) 25,054 (35)
Alemtuzumab 18,690 (9) 13,906 (11) 4784 (7)
Other 3446 (2) 2330 (2) 1116 (2)
No induction 47,728 (23) 25,525 (19) 22,203 (31)
PRA category 2
0–<20 147,492 (74) 93,909 (73) 53,583 (75)
20–80 33,300 (17) 22,142 (17) 11,158 (16)
80 19,059 (10) 12,734 (10) 6325 (9)
Recipient characteristics
Age 0 50  14 50  14 50  14
Male sex 0 123,520 (60) 79,562 (60) 43,958 (61)
Race <1
White 112,467 (55) 71,779 (55) 40,688 (56)
Black 50,769 (25) 33,100 (25) 17,669 (24)
Hispanic 27,584 (14) 18,009 (14) 9575 (13)
Asian 10,165 (5) 6553 (5) 3612 (5)
Other 3274 (2) 2234 (2) 1040 (1)
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Table 1 | Baseline characteristics of eligible study cohort stratiﬁed by presence or absence of documented warm ischemia time
(Continued)
Variable
Proportion of patients
in ﬁnal study cohort
with missing data
Eligible study cohort
N [ 204,263
Final study cohort
(warm time present)
N [ 131,677
Warm time missing
N [ 72,586
Body mass index categories 1
<20 13,456 (7) 8564 (7) 4892 (7)
20–24.9 58,890 (29) 37,613 (29) 21,277 (30)
25–29.9 67,392 (33) 43,638 (33) 23,754 (33)
30–34.9 41,850 (21) 27,493 (21) 14,357 (20)
$35 20,287 (10) 13,226 (10) 7061 (10)
Dialysis vintage 2
Preemptive 36,960 (19) 23,516 (18) 13,444 (19)
0–0.5 years 14,555 (7) 9457 (7) 5098 (7)
0.5–1 year 18,482 (9) 11,633 (9) 6849 (10)
1–2 years 31,497 (16) 19,918 (15) 11,579 (17)
2–3 years 25,596 (13) 16,784 (13) 8812 (13)
3–4 years 20,810 (10) 13,647 (11) 7163 (10)
>4 years 51,572 (26) 34,416 (27) 17,156 (24)
Cause of ESRD 1
Glomerulonephritis 51,464 (26) 33,609 (26) 17,855 (25)
Diabetes 48,967 (24) 31,657 (24) 17,310 (24)
Polycystic kidney disease 19,344 (10) 12,526 (10) 6818 (10)
Hypertension 43,847 (21) 28,604 (22) 15,243 (21)
Other 38,169 (19) 23,878 (18) 14,291 (20)
Comorbidities
Diabetes mellitus <1 63,205 (31) 40,795 (31) 22,410 (31)
Hypertension 156,735 (85) 105,497 (86) 51,238 (84)
Coronary artery disease 14,934 (8) 9572 (8) 5362 (9)
Peripheral vascular disease 7316 (4) 4937 (4) 2379 (4)
Cerebrovascular disease 4901 (3) 3378 (3) 1523 (3)
Prior malignancy 9262 (5) 6218 (5) 3044 (5)
Chronic lung disease 2083 (1) 1416 (1) 667 (1)
Previous kidney transplant 0 25,257 (12) 15,831 (12) 9426 (13)
ESRD, end-stage renal disease; HLA, human leukocyte antigen; PRA, panel reactive antibody.
aCalculated only among deceased-donor recipients.
KK Tennankore et al.: Warm time and transplant outcomes c l i n i ca l i nves t iga t ionits impact on kidney transplant function and patient out-
comes after transplantation. Several single-center studies have
reported more delayed graft function and lower graft survival
with longer warm times.7,9,10 More recently, a longer anas-
tomotic time was found to be associated with reduced long-
term patient survival. Our analysis supports the ﬁndings of
these single-center studies.
Ischemia–reperfusion injury has been proposed to be the
mechanism for early dysfunction related to organ ischemia.
This is an area of intense research interest. Currently there are
several clinical trials examining interventions to ameliorate
ischemia–reperfusion injury in kidney transplantation,
including terminal complement inhibition (NCT01442337),
remote ischemia preconditioning (NCT00975702), potential
effects of different anesthetic agents (NCT011132157), inhi-
bition of apoptosis (NCT00802347), and adhesion molecule
blockade (NCT00298168). It is likely that multiple in-
terventions will be needed to reduce injury. Preventive stra-
tegies that reduce exposure to warm ischemia time would
complement other interventions.
Interestingly, the effect of warm ischemia time appears to
continue well beyond the early period post-transplantation.
This ﬁnding has also been demonstrated in the literature
surrounding acute kidney injury (often due to prolonged
ischemia) that can lead to long-term kidney failure and anKidney International (2016) 89, 648–658increased risk of death.14–16 Therefore, it is biologically
plausible that even small changes in warm ischemia time
inﬂuence long-term outcomes. Although a progressive
increase in warm ischemia time was associated with an
increased hazard for death or graft failure relative to times of
10 to <20 minutes, patients who had warm ischemia times of
0 to <10 minutes were also at higher risk in most adjusted
analyses. We suspect that times less than 10 minutes were
either mistaken entries or were recorded by surgeons who
used cooling jackets or other techniques to keep the organs
cool. This is supported by the ﬁnding that most of the 13,456
reports of warm ischemia times of less than 10 minutes were
either 0 or 1 minute, which would be technically impossible.
More information is needed to understand how and why
these times are so short and whether a cooling jacket, if used,
is effective.17,18
Given the ﬁndings that longer times are associated with
worse outcomes, efforts to reduce warm ischemia time should
be an area of further research. Longer times may be inevitable
for some surgeries (and even the same surgeon) given donor
factors (vessel number, vessel length, vascular disease, or
other anomalies or organ injuries) and recipient characteris-
tics (large body mass, poor vasculature). Although we expect
that all surgeons work to minimize anastomosis time
(a component of warm ischemia time), it is apparent that651
Table 2 | Baseline characteristics of ﬁnal study cohort stratiﬁed by warm ischemia time categories
Variable
Final study cohort
(N [ 131,677)
Warm time
0–<10 minutes
(N [ 13,456)
Warm time
10–<20 minutes
(N [ 3715)
Warm time
20–<30 minutes
(N [ 21,627)
Warm time
30–<40 minutes
(N [ 38,403)
W rm time
40–< 0 minutes
(N 27,058)
Warm time
50–<60 minutes
(N [ 10,818)
Warm time
‡60 minutes
(N [ 16,600)
Donor characteristics
Age (mean years  SD)a 39  16 38  16 38  16 38  16 39  16  16 40  16 39  16
Height (mean meters  SD)a 1.7  0.1 1.7  0.1 1.7  0.1 1.7  0.2 1.7  0.1 1  0.1 1.7  0.1 1.7  0.1
Weight (mean kg  SD)a 79  23 79  23 79  23 78  23 79  23  23 80  23 80  22
Male sex 68,828 (52) 6746 (50) 1910 (51) 10,903 (50) 20,028 (52) 14 53 (53) 5866 (54) 9022 (54)
Race
White 92,276 (70) 9331 (69) 2594 (70) 15,430 (71) 26,921 (70) 18 21 (70) 7634 (71) 11,545 (70)
Black 17,318 (13) 1718 (13) 581 (16) 2846 (13) 4920 (13) 3 49 (13) 1403 (13) 2301 (14)
Hispanic 17,260 (13) 1837 (14) 378 (10) 2546 (12) 5157 (13) 3 60 (14) 1412 (13) 2270 (14)
Other 4822 (4) 570 (4) 162 (4) 804 (4) 1405 (4) 1 28 (4) 369 (3) 484 (3)
Body mass index categories
<20 9998 (8) 992 (8) 267 (7) 1669 (8) 2988 (8) 2 64 (8) 821 (8) 1197 (7)
20–24.9 41,591 (32) 4213 (32) 1172 (32) 7031 (33) 12,218 (33) 8 55 (31) 3363 (32) 5239 (32)
25–29.9 45,162 (35) 4791 (36) 1310 (36) 7492 (35) 13,011 (35) 9 65 (35) 3622 (34) 5571 (34)
30–34.9 21,561 (17) 2187 (17) 603 (17) 3426 (16) 6276 (17) 4 59 (17) 1794 (17) 2816 (17)
$35 10,606 (8) 968 (7) 269 (7) 1519 (7) 3079 (8) 2 83 (9) 1003 (9) 1385 (9)
Donor type
Standard-criteria donor 67,988 (52) 6052 (45) 1698 (46) 10,781 (50) 19,751 (51) 14 21 (53) 6120 (57) 9365 (56)
Expanded-criteria donor 13,102 (10) 986 (7) 273 (7) 1833 (8) 3693 (10) 3 39 (12) 1276 (12) 1902 (11)
Living donor 50,587 (38) 6418 (48) 1744 (47) 9013 (42) 14,959 (39) 9 98 (36) 3422 (32) 5333 (32)
Donor cause of deatha
Anoxia 16,447 (20) 1378 (20) 450 (23) 2708 (21) 4744 (20) 3 28 (21) 1498 (20) 2041 (18)
Cerebrovascular accident 29,375 (36) 2505 (36) 648 (33) 4346 (34) 8399 (36) 6 81 (37) 2737 (37) 4259 (38)
Head trauma 32,754 (40) 2945 (42) 796 (40) 5183 (41) 9553 (41) 6 20 (39) 2934 (40) 4623 (41)
Other 2514 (3) 210 (3) 77 (4) 377 (3) 748 (3) 31 (3) 227 (3) 344 (3)
Donation after circulatory deatha 9199 (11) 691 (10) 383 (19) 1451 (12) 2520 (11) 2 54 (12) 943 (13) 1157 (10)
Donor hepatitis C positivea 1858 (2) 110 (2) 63 (3) 338 (3) 527 (2) 89 (2) 158 (2) 273 (2)
History of diabetes mellitus 5172 (4) 440 (4) 126 (4) 692 (3) 1510 (4) 1 47 (5) 463 (5) 694 (5)
Hypertensiona 21,558 (27) 1784 (26) 481 (25) 3198 (25) 6159 (26) 4 59 (29) 2014 (27) 2963 (26)
Donor serum creatinine >1.5 mg/dla 12,405 (15) 964 (14) 294 (15) 1890 (15) 3699 (16) 2 81 (17) 1070 (14) 1607 (14)
Pulsatile perfusiona 22,043 (27) 1536 (22) 516 (26) 2943 (23) 6324 (27) 4 55 (28) 2289 (31) 3580 (32)
Surgical characteristics
Cold ischemia time (hours) 12 (2–20) 6 (1–17) 8 (1–17) 10 (1–18) 12 (2–19) 13 (2–21) 14 (3–21) 14 (4–22)
Immunologic characteristics
HLA mismatches
0 13,162 (10) 1401 (10) 365 (10) 2115 (10) 3789 (10) 2 46 (10) 1046 (10) 1700 (10)
1 4577 (3) 540 (4) 130 (4) 705 (3) 1288 (3) 95 (3) 367 (3) 652 (4)
2 12,101 (9) 1450 (11) 388 (10) 1991 (9) 3541 (9) 2 35 (9) 954 (9) 1442 (9)
3 24,478 (19) 2749 (21) 752 (20) 4037 (19) 7115 (19) 4 78 (18) 1928 (18) 3119 (19)
4 27,975 (21) 2702 (20) 755 (20) 4680 (22) 8106 (21) 5 26 (22) 2377 (22) 3529 (21)
5 32,407 (25) 3080 (23) 876 (24) 5348 (25) 9401 (25) 6 65 (25) 2772 (26) 4065 (25)
6 16,427 (13) 1477 (11) 431 (12) 2647 (12) 4977 (13) 3 13 (13) 1345 (12) 2037 (12)
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Induction type
Interleukin-2 receptor antagonist 33,250 (25) 4000 (30) 1156 (31) 5268 (24) 8817 (23) 6153 (23) 2788 (26) 5068 (31)
Anti-thymocyte globulin 56,666 (43) 5548 (41) 1413 (38) 9688 (45) 17,337 (45) 11,267 (42) 4589 (42) 6824 (41)
Alemtuzumab 13,906 (11) 851 (6) 364 (10) 1632 (8) 3893 (10) 4618 (17) 1108 (10) 1440 (9)
Other 2330 (2) 346 (3) 27 (1) 315 (1) 703 (2) 485 (2) 189 (2) 265 (2)
No induction 25,525 (19) 2711 (20) 755 (20) 4724 (22) 7653 (20) 4535 (17) 2144 (20) 3003 (18)
PRA category
0–<20 93,909 (73) 10,194 (77) 2748 (76) 15,114 (72) 27,008 (72) 19,123 (72) 7753 (73) 11,969 (73)
20–80 22,142 (17) 2003 (15) 542 (15) 3683 (18) 6622 (18) 4722 (18) 1833 (17) 2737 (17)
>80 12,734 (10) 1041 (8) 333 (9) 2117 (10) 3869 (10) 2700 (10) 1026 (10) 12,734 (10)
Recipient characteristics
Age 50  14 50  14 50  14 50  14 50  14 51  14 51  14 50  13
Male sex 79,562 (60) 8197 (61) 2242 (60) 12,914 (60) 23,171 (60) 16,319 (60) 6643 (61) 10,076 (61)
Race
White 71,779 (54) 7536 (56) 2060 (55) 12,253 (57) 20,988 (55) 14,422 (53) 5833 (54) 8687 (52)
Black 33,100 (25) 2979 (22) 970 (26) 5342 (25) 9436 (25) 6782 (25) 2818 (26) 4773 (29)
Hispanic 18,009 (14) 1974 (15) 362 (10) 2496 (12) 5464 (14) 3952 (15) 1489 (14) 2272 (14)
Asian 6553 (5) 750 (6) 245 (7) 1136 (5) 1895 (5) 1447 (5) 490 (5) 590 (4)
Other 2234 (2) 217 (2) 78 (2) 400 (2) 620 (2) 455 (2) 187 (2) 277 (2)
Body mass index categories
<20 8564 (7) 1023 (8) 273 (7) 1550 (7) 2526 (7) 1656 (6) 609 (6) 927 (6)
20–24.9 37,613 (29) 3974 (30) 1161 (31) 6681 (31) 10,962 (29) 7487 (28) 2908 (27) 4440 (27)
25–29.9 43,638 (33) 4418 (33) 1210 (33) 7193 (34) 12,881 (34) 9046 (34) 3503 (33) 5387 (33)
30–34.9 27,493 (21) 2739 (20) 743 (20) 4262 (20) 7995 (21) 5694 (21) 2438 (23) 3622 (22)
$35 13,226 (10) 1238 (9) 306 (8) 1774 (8) 3692 (10) 3018 (11) 1236 (12) 1962 (12)
Dialysis vintage
Preemptive 23,516 (18) 2854 (21) 748 (21) 4345 (20) 7046 (19) 4692 (18) 1633 (15) 2198 (14)
0–0.5 years 9457 (7) 1065 (8) 294 (8) 1570 (7) 2820 (7) 1939 (7) 709 (7) 1060 (7)
0.5–1 year 11,633 (9) 1267 (10) 331 (9) 1953 (9) 3494 (9) 2263 (8) 903 (8) 1422 (9)
1–2 years 19,918 (15) 1980 (15) 545 (15) 3239 (15) 5907 (16) 3975 (15) 1633 (15) 2639 (16)
2–3 years 16,784 (13) 1573 (12) 425 (12) 2628 (12) 4957 (13) 3395 (13) 1474 (14) 2332 (14)
3–4 years 13,647 (11) 1173 (9) 352 (10) 2141 (10) 3878 (10) 2856 (11) 1259 (12) 1988 (12)
>4 years 34,416 (27) 3201 (24) 952 (26) 5446 (26) 9651 (26) 7545 (28) 3025 (28) 4596 (28)
Cause of ESRD
Glomerulonephritis 33,609 (26) 3498 (26) 1005 (27) 5845 (27) 9889 (26) 6798 (25) 2567 (24) 4007 (24)
Diabetes 31,657 (24) 3182 (24) 789 (21) 4742 (22) 8853 (23) 6814 (25) 2849 (27) 4428 (27)
Polycystic kidney disease 12,526 (10) 1308 (10) 384 (10) 2213 (10) 3744 (10) 2454 (9) 1037 (10) 1386 (8)
Hypertension 28,604 (22) 2802 (21) 849 (23) 4720 (22) 8382 (22) 5840 (22) 2279 (21) 3732 (23)
Other 23,878 (18) 2533 (19) 667 (18) 3920 (18) 7127 (19) 4851 (18) 1947 (18) 2833 (17)
Comorbidities
Diabetes mellitus 40,795 (31) 3976 (30) 1023 (28) 6169 (29) 11,613 (30) 8764 (32) 3646 (34) 5604 (34)
Hypertension 105,497 (86) 10,361 (84) 2992 (86) 17,477 (87) 30,845 (86) 21,387 (86) 8902 (87) 13,533 (86)
Coronary artery disease or angina 9572 (8) 760 (6) 234 (7) 1355 (7) 2637 (8) 2102 (9) 863 (9) 1621 (10)
Peripheral vascular disease 4937 (4) 461 (4) 128 (4) 719 (3) 1405 (4) 1012 (4) 425 (4) 787 (5)
Cerebrovascular disease 3378 (3) 254 (2) 86 (2) 565 (3) 962 (3) 676 (3) 302 (3) 533 (3)
Prior malignancy 6218 (5) 548 (4) 162 (4) 1130 (5) 1991 (5) 1204 (5) 480 (5) 703 (4)
Chronic lung disease 1416 (1) 111 (1) 37 (1) 211 (1) 366 (1) 304 (1) 134 (1) 253 (2)
Previous kidney transplant 15,831 (12) 1523 (11) 348 (9) 2334 (11) 4831 (13) 3330 (12) 1350 (12) 2115 (13)
ESRD, end-stage renal disease; HLA, human leukocyte antigen; PRA, panel reactive antibody.
aAmong deceased-donor recipients only.
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Figure 2 | Proportion of patients with reported ischemia warm times by transplant center (left) and proportion of centers reporting
warm ischemia time (right).
c l i n i ca l i nves t iga t i on KK Tennankore et al.: Warm time and transplant outcomestimes vary widely. Surgical skill is difﬁcult to measure, and
experience is needed to develop these skills. It is not clear
whether all surgeons share the same attitude toward the
importance of warm ischemia time, and this would be an area
for further study. A recent editorial stressed the importance of
developing ways to objectively examine surgical skills.19 Many
transplant centers are teaching institutions, and trainees may
slow the surgical time. Simulation laboratory practice may
help reduce anastomosis times for surgical trainees, and
keeping times less than 30 to 35 minutes may be a benchmark
to improve patient outcomes. Clearly time is not the only
factor in assessing a surgeon’s skill.
The association between warm ischemia time and outcome
also informs the importance of better documentation. A
number of warm ischemia times were missing, as this is a
voluntary variable to report to the United Network for Organ
Sharing (UNOS). Furthermore, as of 2015, warm ischemia
time will no longer be captured in UNOS data reporting
forms. Acknowledging its effect on long-term outcome, sys-
tematic and accurate capture of all components of warm
ischemia (including time between removal from cooling and
start of anastomosis, anastomosis time, and reperfusion time)
should be considered.
We focused on hard end points in this study rather than
intermediary outcomes such as delayed graft function,Figure 3 | Distribution of warm ischemia time (truncated at 120
minutes).
654rejection rates, other complications, or length of stays in
hospital. Warm ischemia time is a component of a recent
prediction model for delayed graft function.20 Nonetheless, in
our study the relative hazard for the primary outcome was not
different among those with or without delayed graft function.
This emphasizes that delayed graft function does not modify
the association between warm time and outcome, and high-
lights that the effect of warm ischemia time is irrespective of
whether or not patients develop delayed graft function.
This study has a number of strengths. We used data from a
large, comprehensive, national registry of kidney transplant
recipients, increasing the generalizability of our results. The
large number of outcomes allowed us to adjust for numerous
recipient and donor factors without creating instability in our
multivariable models. The ﬁndings of our primary analysis
were conﬁrmed in several sensitivity analyses using different
patient sub-cohorts and outcomes of death-censored graft
failure and death with graft function.
There are limitations to this study that need to be
considered in the context of study design, available data, and
implications for research. Although we accounted for a
number of potential confounders in the primary analysis,
there may have been residual confounding. Information on
other factors that may have inﬂuenced warm ischemia time
(e.g., ancillary devices such as cooling jackets) was not
available. It is possible that some or many of the warm
ischemia times of less than 10 minutes (including 0 minutes)
were the result of use of these devices as opposed to coding
errors. Details around the components of warm ischemia
time (including anastomosis time) were unavailable. There
were many patients who were not included in this analysis
due to unavailable warm ischemia times, and it is impossible
to ensure the accuracy of warm ischemia time reporting
among those who were included. Nonetheless, the ﬁndings of
our primary analysis were similar even after analyzing only
high-reporting centers or patients transplanted after 2005.
Furthermore, characteristic differences between those with
and without warm ischemia times were minimal. We expect
that there is a progressive increase in adverse events with
longer warm times consistent with the non-transplant liter-
ature,11–13 but it is not clear that there is an ideal time below
which there is no effect. There are also limitations with
respect to the impact of this ﬁnding on subsequent research.Kidney International (2016) 89, 648–658
Figure 4 | Cumulative failure (graft failure or death) for categories of warm ischemia time (log-rank P < 0.001).
KK Tennankore et al.: Warm time and transplant outcomes c l i n i ca l i nves t iga t ionAlthough this study highlights the effect of warm ischemia
time on outcome, this may not necessarily be modiﬁable.
Unavoidable surgical complications and difﬁcult vascular
anastomoses due to recipient–donor vessel quality may limit
ability to improve on anastomotic time (hence warm
ischemia time). Finally, this study does not reveal the
underlying mechanism that results in progressive graft loss
and patient mortality. A prolonged warm ischemia time may
be a marker for other factors that were either unknown or
unmeasured in this study.
Warm ischemia time is an important and potentially
modiﬁable factor that inﬂuences long-term graft and patient
survival. Accurate and systematic reporting of warm ischemia
time will be crucial if efforts to reduce it are undertaken.
Strategies to reduce warm ischemia time (including the
establishment of surgical benchmarks) should be considered
as priority areas for future research.MATERIALS AND METHODS
Design
We conducted a cohort study of United States adult kidney trans-
plant recipients between 1 January 2000 and 31 December 2013. This
study used data from the Scientiﬁc Registry of Transplant Recipients
(SRTR). The SRTR data system includes data on all donors,Table 3 | Five- and ten-year composite event survival proba-
bilities for each warm ischemia time category
Warm ischemia
time category
5-year survival
[95% conﬁdence interval]
10-year survival
[95% conﬁdence interval]
0–<10 minutes 78 [77–79] 54 [53–56]
10–<20 minutes 80 [78–81] 61 [58–64]
20–<30 minutes 78 [78–79] 55 [54–57]
30–<40 minutes 77 [76–77] 53 [53–54]
40–<50 minutes 75 [75–76] 52 [51–53]
50–<60 minutes 74 [73–75] 51 [49–52]
$60 minutes 73 [72–74] 50 [49–51]
Kidney International (2016) 89, 648–658waitlisted candidates, and transplant recipients in the United States,
submitted by the members of the Organ Procurement and Trans-
plantation Network (OPTN). The Health Resources and Services
Administration, US Department of Health and Human Services,
provides oversight to the activities of the OPTN and SRTR con-
tractors. We excluded recipients who were <18 years of age, received
multiple organs, or had either en bloc or dual kidney transplants.
Exposure
The primary exposure was warm ischemia time collected from the
United Network for Organ Sharing (UNOS) database. This was
deﬁned as the number of minutes from organ removal from cold
storage to reperfusion with warm blood (venous or arterial) and
included surgical warm ischemia time (anastomosis time). Warm
ischemia time was categorized in increments of 0 to <10, 10 to <20,
20 to <30, 30 to <40, 40 to <50, 50 to <60, and $60 minutes.
Acknowledging that warm ischemia times of <10 minutes would be
surgically difﬁcult to perform (and potentially due to data entry
errors), we selected warm ischemia times of 10 to <20 minutes as
the reference group.
Outcome
The primary outcome was the composite of death with graft function
or graft loss. Graft loss was deﬁned as the need for chronic dialysis or
preemptive retransplantation. The component outcomes of the
composite (i.e., death-censored graft failure and death with graft
function) were examined separately in secondary analyses. Censoring
occurred at losses to follow-up and the date of last follow-up
(2 December 2014).
Data collection
Potential confounders of interest were collected from the SRTR
database. These variables included:
(i) recipient factors: age, sex, race, cause of end-stage renal disease,
body mass index, dialysis vintage, history of diabetes, coronary
artery disease, peripheral vascular disease, hypertension, cere-
brovascular disease, chronic lung disease, prior malignancy, and
prior kidney transplant.655
Table 4 | Unadjusted and adjusted Cox survival analysis for death or graft failure
Model
Warm time
(minutes)
Death or graft failure
HR [95% CI]
Death-censored graft failure
HR [95% CI]
Death with graft function
HR [95% CI]
Unadjusted
Patients/Events 131,677/35,901 131,677/20,032 131,677/15,869
0–<10 1.13 [1.04–1.21] 1.09 [0.99–1.21] 1.17 [1.04–1.31]
10–<20 Ref. Ref. Ref.
20–<30 1.08 [1.00–1.16] 1.04 [0.94–1.15] 1.13 [1.01–1.27]
30–<40 1.17 [1.09–1.26] 1.17 [1.07–1.29] 1.17 [1.05–1.30]
40–<50 1.25 [1.16–1.34] 1.24 [1.12–1.36] 1.26 [1.13–1.41]
50–<60 1.31 [1.22–1.42] 1.32 [1.20–1.47] 1.30 [1.16–1.46]
$60 1.38 [1.28–1.48] 1.38 [1.26–1.53] 1.37 [1.23–1.53]
Adjusted with imputation
Patients/Events 131,677/35,901 131,677/20,032 131,677/15,869
0–<10 1.17 [1.09–1.26] 1.15 [1.04–1.27] 1.19 [1.06–1.33]
10–<20 Ref. Ref. Ref.
20–<30 1.07 [0.99–1.15] 1.04 [0.94–1.14] 1.11 [0.99–1.24]
30–<40 1.13 [1.06–1.22] 1.13 [1.03–1.24] 1.14 [1.02–1.26]
40–<50 1.17 [1.09–1.26] 1.17 [1.06–1.29] 1.18 [1.06–1.32]
50–<60 1.20 [1.12–1.30] 1.23 [1.11–1.36] 1.18 [1.05–1.32]
$60 1.23 [1.15–1.33] 1.25 [1.13–1.37] 1.23 [1.10–1.38]
Adjusted: complete case
analysis
Patients/Events 92,035/24,642 92,035/13,601 92,035/11,041
0–<10 1.16 [1.06–1.27] 1.13 [1.00–1.28] 1.19 [1.04–1.37]
10–<20 Ref. Ref. Ref.
20–<30 1.08 [0.99–1.18] 1.04 [0.92–1.17] 1.13 [0.99–1.29]
30–<40 1.13 [1.04–1.23] 1.13 [1.00–1.26] 1.14 [1.00–1.29]
40–<50 1.18 [1.08–1.28] 1.15 [1.02–1.29] 1.23 [1.07–1.40]
50–<60 1.20 [1.10–1.32] 1.19 [1.05–1.35] 1.23 [1.07–1.42]
$60 1.26 [1.15–1.38] 1.24 [1.10–1.40] 1.29 [1.13–1.47]
Adjusted for donor characteristics: donor type (living, standard, expanded criteria), donor race, donor sex, donor diabetes status, donor body mass index categories;
immunologic characteristics: number of human leukocyte antigen mismatches, panel reactive antibody categories, induction type; surgical characteristics: cold ischemia time;
and recipient characteristics: age, sex, gender, cause of end-stage renal disease, dialysis vintage, diabetes, coronary artery disease, hypertension, cerebrovascular disease,
peripheral vascular disease, chronic lung disease, prior malignancy, previous kidney transplant, body mass index categories.
CI, conﬁdence interval; HR, relative hazard.
c l i n i ca l i nves t iga t i on KK Tennankore et al.: Warm time and transplant outcomes(ii) donor factors: type (living donor, standard-criteria deceased
donor, expanded-criteria deceased donor21), sex, race, body
mass index, and history of diabetes. For deceased-donor re-
cipients, additional variables considered in the kidney donor
risk index22 were assessed (age, height, weight, history of
hypertension, cerebrovascular accident as cause of death, serum
creatinine >1.5 mg/dl, hepatitis C virus status, and donation
after circulatory death status).
(iii) immunologic factors (peak panel reactive antibody, human
leukocyte antigen mismatch, induction immunosuppression).
(iv) surgical factors (cold ischemia time and hypothermic pulsatile
perfusion for kidneys procured from deceased donors).
Missing data in confounders were treated by multiple imputation
using chained equations.23 All variables with complete data
(including the outcome of interest) were used in the conditional
models, and 10 data sets were created. In a restricted analysis, the
relative hazard and 95% conﬁdence interval were also calculated
among “complete cases.” For subgroup analyses conducted among
living-donor and deceased-donor recipients, separate multiple
imputation models were used incorporating variables used in the
subgroup analyses.
Analysis
Baseline characteristics were reported for patients with warm
ischemia times of 0 to $60 minutes and those without documented656warm ischemia times. Among those patients with available warm
ischemia times (the ﬁnal study cohort) we also indicated the pro-
portion of patients that were missing data for each baseline charac-
teristic. Baseline characteristics were also reported for each warm
ischemia time category. Characteristics were reported as frequencies
and proportions for categorical variables and mean  SD for
continuous variables. The proportion of patients with reported versus
missing warm ischemia time was graphically displayed by center. The
association between warm ischemia time and the primary outcome
was visually displayed using cumulative failure curves (Kaplan–Meier
failure function), and distributions were compared using the log-rank
test. Time to death or graft failure for categories of surgical warm
ischemia time (reference group of 10 to <20 minutes) was analyzed
in a multivariable Cox proportional hazards model. For the primary
analysis, we included donor factors (type, sex, race, diabetes status,
and categories of body mass index), recipient factors (age, sex, race,
cause of end-stage renal disease, categories of body mass index,
dialysis vintage, comorbidities, and prior kidney transplant), and
surgical and immunologic factors (cold ischemia time, number of
human leukocyte antigen mismatches, type of induction, and cate-
gories of peak panel reactive antibody). Relative hazards and 95%
conﬁdence intervals for each confounding variable in the Cox pro-
portional hazards model were also reported. Proportionality was
examined using log-log plots. Sensitivity analyses were conducted
evaluating outcomes before and after 1 year of follow-up. TheKidney International (2016) 89, 648–658
Table 5 | Sensitivity analyses
Group
Relative hazard
[95% conﬁdence interval]
2005–2013 era: 97,627
patients/20,107 events
0–<10 1.15 [1.05–1.26]
10–<20 Ref.
20–<30 1.07 [0.98–1.16]
30–<40 1.12 [1.03–1.22]
40–<50 1.18 [1.08–1.28]
50–<60 1.17 [1.06–1.29]
$60 1.24 [1.13–1.35]
From center with $75%
warm ischemia time
reporting: 83,787
patients/23,313 events
0–<10 1.12 [1.01–1.26]
10–<20 Ref.
20–<30 1.09 [0.98–1.21]
30–<40 1.15 [1.04–1.27]
40–<50 1.21 [1.09–1.35]
50–<60 1.24 [1.11–1.38]
$60 1.26 [1.13–1.40]
Restricted to ﬁrst kidney
transplant recipients:
115,846 patients/31,296 events
0–<10 1.19 [1.04–1.22]
10–<20 Ref.
20–<30 1.08 [1.00–1.16]
30–<40 1.14 [1.06–1.23]
40–<50 1.18 [1.09–1.27]
50–<60 1.23 [1.13–1.33]
$60 1.24 [1.15–1.34]
Complete cohort using different
warm ischemia time categories:
131,677 patients/35,091 events
0–<10 1.11 [1.06–1.15]
10–<30 Ref.
30–<60 1.09 [1.06–1.13]
60–<90 1.15 [1.10–1.19]
$90 1.22 [1.15–1.29]
Adjusted for donor characteristics: donor type (living, standard, expanded criteria),
donor race, donor sex, donor diabetes status, donor body mass index categories;
immunologic characteristics: number of human leukocyte antigen mismatches,
panel reactive antibody categories, induction type; surgical characteristics: cold
ischemia time; and recipient characteristics: age, sex, gender, cause of end-stage
renal disease, dialysis vintage, diabetes, coronary artery disease, hypertension, ce-
rebrovascular disease, peripheral vascular disease, chronic lung disease, prior ma-
lignancy, previous kidney transplant, body mass index categories.
KK Tennankore et al.: Warm time and transplant outcomes c l i n i ca l i nves t iga t ionassociation between warm ischemia time and the composite event
was also assessed in a priori subgroup analyses: patients with or
without delayed graft function (deﬁned as need for dialysis in the ﬁrst
week post-transplantation), and among living- and deceased-donor
recipients. For the latter, we included variables in the kidney donor
risk index22 (with the exception of en bloc transplants) and presence
or absence of hypothermic pulsatile perfusion in the adjusted model.
Among deceased donors, outcomes were also assessed in the sub-
group of patients who received a transplant from a donation-after-
circulatory-death donor. Finally, a number of additional sensitivity
analyses were conducted to examine the association between warm
ischemia time and the composite outcome: among patients from high
warm ischemia time–reporting centers ($75%), after restriction of
the cohort to a more contemporary era (2005–2013), after exclusion
of patients with a previous kidney transplant, and among all patientsKidney International (2016) 89, 648–658using different warm ischemia time categories (<10 minutes, 10
to <30 minutes, 30 to <60 minutes, 60–90 minutes, and $90 mi-
nutes). All statistical analyses were performed using Stata version 13.1
(Stata Corp., College Station, TX). A 2-sided P value < 0.05 was
considered statistically signiﬁcant.
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